Q3 EPS Estimates for Vera Therapeutics Decreased by Wedbush

Key Points

• Wedbush has reduced its Q3 2025 EPS estimates for Vera Therapeutics from ($0.79) to ($1.16), maintaining a "Neutral" rating with a price target of $26.00.
• The company's latest earnings report showed a loss of ($1.20) EPS, missing the consensus estimate by ($0.38).
• Vera Therapeutics has a current consensus rating of "Moderate Buy" from analysts, with an average target price of $65.00.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at Wedbush reduced their Q3 2025 EPS estimates for shares of Vera Therapeutics in a research report issued on Tuesday, August 5th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($1.16) per share for the quarter, down from their prior estimate of ($0.79). Wedbush has a "Neutral" rating and a $26.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($4.37) EPS, Q1 2026 earnings at ($1.23) EPS, Q2 2026 earnings at ($1.32) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($5.03) EPS, FY2027 earnings at ($4.12) EPS, FY2028 earnings at ($2.55) EPS and FY2029 earnings at ($1.49) EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period in the previous year, the firm earned ($0.62) EPS.

Several other analysts also recently weighed in on VERA. Cantor Fitzgerald reduced their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Wolfe Research reaffirmed a "peer perform" rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $85.00 target price (up from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $63.00.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA traded down $0.33 during mid-day trading on Thursday, reaching $19.46. The company's stock had a trading volume of 612,727 shares, compared to its average volume of 1,285,014. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $51.61. The stock has a market capitalization of $1.24 billion, a P/E ratio of -5.44 and a beta of 1.17. The stock has a 50-day moving average of $22.97 and a two-hundred day moving average of $25.02. The company has a debt-to-equity ratio of 0.16, a quick ratio of 17.03 and a current ratio of 17.03.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Huntington National Bank purchased a new stake in Vera Therapeutics in the fourth quarter worth about $26,000. GF Fund Management CO. LTD. bought a new stake in Vera Therapeutics during the fourth quarter valued at about $56,000. Quarry LP increased its holdings in shares of Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after purchasing an additional 500 shares during the last quarter. AlphaQuest LLC grew its position in Vera Therapeutics by 404.7% in the first quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock worth $96,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Fifth Third Bancorp purchased a new position in shares of Vera Therapeutics during the second quarter valued at approximately $102,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Insider Buying and Selling

In other Vera Therapeutics news, Director Patrick G. Enright bought 40,607 shares of Vera Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was bought at an average cost of $22.35 per share, with a total value of $907,566.45. Following the completion of the acquisition, the director directly owned 3,596,593 shares in the company, valued at approximately $80,383,853.55. The trade was a 1.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 16.30% of the stock is owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.